Overview

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Status:
Completed

Trial end date:
2019-01-22

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the efficacy and safety of enzalutamide or alternative AA therapy in CRPC participants who were previously treated with a combined androgen blockade therapy which included bicalutamide (Bic-CAB). Efficacy and safety of enzalutamide and alternative AA therapy will be evaluated, and effective therapy against CRPC after treatment with Bic-CAB will be investigated.

Phase:

Phase 2

Details

Lead Sponsor:

Taro Iguchi, MD, PHD

Collaborator:

Astellas Pharma Inc

Treatments:

Flutamide